Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Net Income towards Common Stockholders: 2009-2021

Historic Net Income towards Common Stockholders for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Dec 2021 value amounting to -$85.5 million.

  • Avadel Pharmaceuticals' Net Income towards Common Stockholders fell 894.24% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$88.2 million, marking a year-over-year decrease of 514.63%. This contributed to the annual value of -$85.5 million for FY2021, which is 1253.58% down from last year.
  • Per Avadel Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at -$85.5 million for FY2021, which was down 1,253.58% from -$6.3 million recorded in FY2020.
  • Avadel Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $68.3 million for FY2017, and its period low was -$95.3 million during FY2018.
  • For the 3-year period, Avadel Pharmaceuticals' Net Income towards Common Stockholders averaged around -$56.0 million, with its median value being -$76.0 million (2019).
  • In the last 5 years, Avadel Pharmaceuticals' Net Income towards Common Stockholders surged by 265.40% in 2017 and then slumped by 1,253.58% in 2021.
  • Over the past 5 years, Avadel Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at $68.3 million in 2017, then plummeted by 239.60% to -$95.3 million in 2018, then increased by 20.22% to -$76.0 million in 2019, then skyrocketed by 91.69% to -$6.3 million in 2020, then tumbled by 1,253.58% to -$85.5 million in 2021.